
Luigi Bubacco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1402576/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype. Molecular Therapy, 2022, 30, 1465-1483.	3.7	9
2	The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain Research, 2022, 1778, 147781.	1.1	7
3	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. Journal of Neuroinflammation, 2022, 19, 50.	3.1	26
4	The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, 32.	2.5	19
5	Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges. International Journal of Molecular Sciences, 2022, 23, 398.	1.8	30
6	LRRK2 as a target for modulating immune system responses. Neurobiology of Disease, 2022, 169, 105724.	2.1	11
7	Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease. Acta Neuropathologica, 2022, 144, 81-106.	3.9	22
8	Waterâ€Soluble Melanin–Protein–Fe/Cu Conjugates Derived from Norepinephrine as Reliable Models for Neuromelanin of Human Brain <i>Locus Coeruleus</i> . Angewandte Chemie - International Edition, 2022, 61, .	7.2	2
9	Extracellular clusterin limits the uptake of αâ€synuclein fibrils by murine and human astrocytes. Glia, 2021, 69, 681-696.	2.5	32
10	Photoresponsive Prionâ€Mimic Foldamer to Induce Controlled Protein Aggregation. Angewandte Chemie - International Edition, 2021, 60, 5173-5178.	7.2	9
11	Photoresponsive Prionâ€Mimic Foldamer to Induce Controlled Protein Aggregation. Angewandte Chemie, 2021, 133, 5233-5238.	1.6	1
12	Ditopic Chelators of Dicopper Centers for Enhanced Tyrosinases Inhibition. Chemistry - A European Journal, 2021, 27, 4384-4393.	1.7	6
13	<scp>α‣ynuclein</scp> evokes <scp>NLRP3</scp> inflammasomeâ€mediated <scp>IL</scp> â€1β secretion f primary human microglia. Glia, 2021, 69, 1413-1428.	rom 2.5	58
14	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. Current Neuropharmacology, 2021, 19, 1618-1639.	1.4	9
15	Parkinson's Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance. Molecular Neurobiology, 2021, 58, 3119-3140.	1.9	54
16	Too much for your own good: Excessive dopamine damages neurons and contributes to Parkinson's disease. Journal of Neurochemistry, 2021, 158, 833-836.	2.1	5
17	Inhibition of Ceramide Synthesis Reduces α-Synuclein Proteinopathy in a Cellular Model of Parkinson's Disease. International Journal of Molecular Sciences, 2021, 22, 6469.	1.8	17
18	Alpha-synuclein pathology and enteric glia in advanced Parkinson's disease: A study from gastrointestinal biopsies. Journal of the Neurological Sciences, 2021, 429, 119460.	0.3	2

#	Article	IF	CITATIONS
19	Comprehensive Structural and Thermodynamic Analysis of Prefibrillar WT α-Synuclein and Its G51D, E46K, and A53T Mutants by a Combination of Small-Angle X-ray Scattering and Variational Bayesian Weighting. Journal of Chemical Information and Modeling, 2020, 60, 5265-5281.	2.5	6
20	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. Npj Parkinson's Disease, 2020, 6, 18.	2.5	120
21	Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 685-695.	1.9	21
22	Semisynthetic and Enzymeâ€Mediated Conjugate Preparations Illuminate the Ubiquitinationâ€Dependent Aggregation of Tau Protein. Angewandte Chemie, 2020, 132, 6669-6673.	1.6	2
23	Unsaturated Fatty Acid-Induced Conformational Transitions and Aggregation of the Repeat Domain of Tau. Molecules, 2020, 25, 2716.	1.7	15
24	Semisynthetic Modification of Tau Protein with Di-Ubiquitin Chains for Aggregation Studies. International Journal of Molecular Sciences, 2020, 21, 4400.	1.8	20
25	Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?. Biomolecules, 2020, 10, 195.	1.8	107
26	Semisynthetic and Enzymeâ€Mediated Conjugate Preparations Illuminate the Ubiquitinationâ€Dependent Aggregation of Tau Protein. Angewandte Chemie - International Edition, 2020, 59, 6607-6611.	7.2	24
27	Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 68.	1.7	56
28	Alpha-synuclein and neuroinflammation in Parkinson's disease. , 2020, , 431-446.		1
29	Fibrils of α-Synuclein Abolish the Affinity of Cu ²⁺ -Binding Site to His50 and Induce Hopping of Cu ²⁺ lons in the Termini. Inorganic Chemistry, 2019, 58, 10920-10927.	1.9	12
30	Neuronal Proteins as Targets of 3-Hydroxykynurenine: Implications in Neurodegenerative Diseases. ACS Chemical Neuroscience, 2019, 10, 3731-3739.	1.7	8
31	Impaired dopamine metabolism in Parkinson's disease pathogenesis. Molecular Neurodegeneration, 2019, 14, 35.	4.4	187
32	Determination of ATP, ADP, and AMP Levels by Reversed-Phase High-Performance Liquid Chromatography in Cultured Cells. Methods in Molecular Biology, 2019, 1925, 223-232.	0.4	20
33	Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells. Neurotoxicity Research, 2019, 36, 746-755.	1.3	4
34	Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils. Neurobiology of Disease, 2019, 129, 67-78.	2.1	53
35	Ceramides in Parkinson's Disease: From Recent Evidence to New Hypotheses. Frontiers in Neuroscience, 2019, 13, 330.	1.4	41
36	Inhibition of the deubiquitinase USP8 corrects a Drosophila PINK1 model of mitochondria dysfunction. Life Science Alliance, 2019, 2, e201900392.	1.3	22

#	Article	IF	CITATIONS
37	Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss. Human Molecular Genetics, 2018, 27, 1618-1629.	1.4	28
38	Synapsin III is a key component of αâ€ s ynuclein fibrils in Lewy bodies of PD brains. Brain Pathology, 2018, 28, 875-888.	2.1	37
39	Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View. Molecular Neurobiology, 2018, 55, 8754-8763.	1.9	53
40	<scp>USP</scp> 14 inhibition corrects an <i>inÂvivo</i> model of impaired mitophagy. EMBO Molecular Medicine, 2018, 10, .	3.3	69
41	Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. Journal of Neuroinflammation, 2018, 15, 297.	3.1	33
42	Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Acta Neuropathologica, 2018, 136, 621-639.	3.9	53
43	Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson's Disease. , 2018, 9, 716.		42
44	Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease. ACS Chemical Neuroscience, 2018, 9, 2849-2858.	1.7	42
45	Impacts of increased α-synuclein on clathrin-mediated endocytosis at synapses: implications for neurodegenerative diseases. Neural Regeneration Research, 2018, 13, 647.	1.6	16
46	DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Scientific Reports, 2017, 7, 40699.	1.6	107
47	Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?. Biochemical Society Transactions, 2017, 45, 261-267.	1.6	31
48	GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. Human Molecular Genetics, 2017, 26, 2747-2767.	1.4	67
49	Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson's Disease. ACS Chemical Neuroscience, 2017, 8, 501-512.	1.7	40
50	Pressure effects on α-synuclein amyloid fibrils: An experimental investigation on their dissociation and reversible nature. Archives of Biochemistry and Biophysics, 2017, 627, 46-55.	1.4	11
51	Molecular Insights and Functional Implication of LRRK2 Dimerization. Advances in Neurobiology, 2017, 14, 107-121.	1.3	12
52	Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications, 2017, 5, 22.	2.4	73
53	High-Pressure-Driven Reversible Dissociation of α-Synuclein Fibrils Reveals Structural Hierarchy. Biophysical Journal, 2017, 113, 1685-1696.	0.2	16
54	Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease. Neurobiology of Disease, 2017, 108, 65-72.	2.1	74

#	Article	IF	CITATIONS
55	2-Hydroxypyridine- <i>N</i> -oxide-Embedded Aurones as Potent Human Tyrosinase Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 55-60.	1.3	38
56	Metal lons, Dopamine and Oxidaitive Stress in Parkinson's Disease. Impact, 2017, 2017, 9-11.	0.0	1
57	α-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling. Frontiers in Cellular Neuroscience, 2017, 11, 388.	1.8	34
58	PAK6 Phosphorylates 14-3-3Î ³ to Regulate Steady State Phosphorylation of LRRK2. Frontiers in Molecular Neuroscience, 2017, 10, 417.	1.4	46
59	Protective effects of superoxide dismutation activity in genetic models of Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e88.	1.1	Ο
60	LRRK2 deficiency impacts ceramide metabolism in brain. Biochemical and Biophysical Research Communications, 2016, 478, 1141-1146.	1.0	50
61	α-Synuclein is a Novel Microtubule Dynamase. Scientific Reports, 2016, 6, 33289.	1.6	79
62	LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Molecular Neurodegeneration, 2016, 11, 1.	4.4	128
63	Entrapment and characterization of functional allosteric conformers of hemocyanin in sol–gel matrices. RSC Advances, 2016, 6, 16868-16881.	1.7	0
64	Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity. Journal of Biological Chemistry, 2016, 291, 9257-9267.	1.6	56
65	Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing Research Reviews, 2016, 26, 62-71.	5.0	36
66	Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?. Current Topics in Medicinal Chemistry, 2016, 16, 3033-3047.	1.0	54
67	Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View. Current Neuropharmacology, 2016, 14, 260-271.	1.4	82
68	Leucineâ€rich repeat kinase 2 interacts with p21â€activated kinase 6 to control neurite complexity in mammalian brain. Journal of Neurochemistry, 2015, 135, 1242-1256.	2.1	57
69	Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. Journal of Neuroinflammation, 2015, 12, 230.	3.1	99
70	Effects of Trehalose on Thermodynamic Properties of Alpha-synuclein Revealed through Synchrotron Radiation Circular Dichroism. Biomolecules, 2015, 5, 724-734.	1.8	26
71	Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation. PLoS ONE, 2015, 10, e0136769.	1.1	55
72	Differences in the Binding of Copper(I) to α- and β-Synuclein. Inorganic Chemistry, 2015, 54, 265-272.	1.9	32

#	Article	IF	CITATIONS
73	NADH fluorescence lifetime is an endogenous reporter of αâ€synuclein aggregation in live cells. FASEB Journal, 2015, 29, 2484-2494.	0.2	24
74	Binding interactions of agents that alter $\hat{I}\pm$ -synuclein aggregation. RSC Advances, 2015, 5, 11577-11590.	1.7	22
75	The functional dissection of the plasma corona of SiO ₂ -NPs spots histidine rich glycoprotein as a major player able to hamper nanoparticle capture by macrophages. Nanoscale, 2015, 7, 17710-17728.	2.8	49
76	Human Tyrosinase Produced in Insect Cells: A Landmark for the Screening of New Drugs Addressing its Activity. Molecular Biotechnology, 2015, 57, 45-57.	1.3	34
77	Peptides as Modulators of α-Synuclein Aggregation. Protein and Peptide Letters, 2015, 22, 354-361.	0.4	7
78	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience, 2014, 7, 49.	1.4	82
79	Interactions of metal ions with $\hat{I}\pm$ synuclein and amyloid \hat{I}^2 peptides. , 2014, , .		Ο
80	LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. Journal of Neuroinflammation, 2014, 11, 52.	3.1	148
81	Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2014-2024.	1.1	72
82	DJ-1 Is a Copper Chaperone Acting on SOD1 Activation. Journal of Biological Chemistry, 2014, 289, 10887-10899.	1.6	76
83	Investigation of Bindingâ€Site Homology between Mushroom and Bacterial Tyrosinases by Using Aurones as Effectors. ChemBioChem, 2014, 15, 1325-1333.	1.3	26
84	Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro. ACS Chemical Neuroscience, 2014, 5, 30-38.	1.7	60
85	Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?. Ageing Research Reviews, 2014, 13, 107-114.	5.0	66
86	Probing kojic acid binding to tyrosinase enzyme: insights from a model complex and QM/MM calculations. Chemical Communications, 2014, 50, 308-310.	2.2	25
87	Biophysical groundwork as a hinge to unravel the biology of <i>α</i> -synuclein aggregation and toxicity. Quarterly Reviews of Biophysics, 2014, 47, 1-48.	2.4	32
88	NADH is an Endogenous Reporter for Alpha-Synuclein Aggregation in Live Cells. Biophysical Journal, 2014, 106, 56a.	0.2	0
89	The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. Human Molecular Genetics, 2014, 23, 5615-5629.	1.4	56
90	A Novel Prion Protein-Tyrosine Hydroxylase Interaction. CNS and Neurological Disorders - Drug Targets, 2014, 13, 896-908.	0.8	3

#	Article	IF	CITATIONS
91	GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Human Molecular Genetics, 2013, 22, 1140-1156.	1.4	124
92	Copper(I)-α-Synuclein Interaction: Structural Description of Two Independent and Competing Metal Binding Sites. Inorganic Chemistry, 2013, 52, 1358-1367.	1.9	58
93	Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis. Journal of Biological Inorganic Chemistry, 2013, 18, 81-93.	1.1	27
94	Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. FASEB Journal, 2013, 27, 2101-2110.	0.2	42
95	Small molecules interacting with α-synuclein: antiaggregating and cytoprotective properties. Amino Acids, 2013, 45, 327-338.	1.2	52
96	Unsymmetrical Binding Modes of the HOPNO Inhibitor of Tyrosinase: From Model Complexes to the Enzyme. Chemistry - A European Journal, 2013, 19, 3655-3664.	1.7	16
97	α-Synuclein Oligomers Induced by Docosahexaenoic Acid Affect Membrane Integrity. PLoS ONE, 2013, 8, e82732.	1.1	47
98	Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies. PLoS ONE, 2013, 8, e55375.	1.1	465
99	Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?. Biochemical Society Transactions, 2012, 40, 1095-1101.	1.6	20
100	Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53. Journal of Biological Chemistry, 2012, 287, 18738-18749.	1.6	61
101	Parkinson's disease and immune system: is the culprit LRRKing in the periphery?. Journal of Neuroinflammation, 2012, 9, 94.	3.1	34
102	Alpha-synuclein pore forming activity upon membrane association. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2876-2883.	1.4	86
103	Worm-Like Ising Model for Protein Mechanical Unfolding under the Effect of Osmolytes. Biophysical Journal, 2012, 102, 342-350.	0.2	13
104	Single-Molecule Force Spectroscopy of Chimeric Polyprotein Constructs Containing Intrinsically Disordered Domains. , 2012, 896, 47-56.		5
105	Cloning and characterization of cytoplasmic carbonic anhydrase from gills of four Antarctic fish: insights into the evolution of fish carbonic anhydrase and cold adaptation. Polar Biology, 2012, 35, 1587-1600.	0.5	23
106	Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinson's Disease. PLoS ONE, 2012, 7, e38026.	1.1	59
107	Covalent α-Synuclein Dimers: Chemico-Physical and Aggregation Properties. PLoS ONE, 2012, 7, e50027.	1.1	35
108	Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of Homodimers. PLoS ONE, 2012, 7, e43472.	1.1	92

#	Article	IF	CITATIONS
109	Exosomes-associated neurodegeneration and progression of Parkinson's disease. American Journal of Neurodegenerative Disease, 2012, 1, 217-25.	0.1	55
110	Designed Hairpin Peptides Interfere with Amyloidogenesis Pathways: Fibril Formation and Cytotoxicity Inhibition, Interception of the Preamyloid State. Biochemistry, 2011, 50, 8202-8212.	1.2	50
111	Investigation of Streptomyces antibioticus tyrosinase reactivity toward chlorophenols. Archives of Biochemistry and Biophysics, 2011, 505, 67-74.	1.4	37
112	Insights into the oligomerization process of the C-terminal domain of human plasma membrane Ca2+-ATPase. Archives of Biochemistry and Biophysics, 2011, 506, 194-200.	1.4	2
113	Raman, UV–vis, and CD Spectroscopic Studies of Dodecameric Oxyhemocyanin from <i>Carcinus aestuarii</i> . Chemistry Letters, 2011, 40, 1360-1362.	0.7	1
114	Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?. Molecular Neurodegeneration, 2011, 6, 6.	4.4	36
115	Observing the osmophobic effect in action at the single molecule level. Proteins: Structure, Function and Bioinformatics, 2011, 79, 2214-2223.	1.5	15
116	Singleâ€Moleculeâ€Level Evidence for the Osmophobic Effect. Angewandte Chemie - International Edition, 2011, 50, 4394-4397.	7.2	25
117	Structural and Morphological Characterization of Aggregated Species of α-Synuclein Induced by Docosahexaenoic Acid. Journal of Biological Chemistry, 2011, 286, 22262-22274.	1.6	101
118	α-Synuclein overexpression increases dopamine toxicity in BE(2)-M17 cells. BMC Neuroscience, 2010, 11, 41.	0.8	44
119	Structural Basis of the Lactate-dependent Allosteric Regulation of Oxygen Binding in Arthropod Hemocyanin. Journal of Biological Chemistry, 2010, 285, 19338-19345.	1.6	8
120	Structural Characterization of a High Affinity Mononuclear Site in the Copper(II)-α-Synuclein Complex. Journal of the American Chemical Society, 2010, 132, 18057-18066.	6.6	36
121	Insights on Channel-Like Activity of Membrane Bound Alpha-Synuclein. Biophysical Journal, 2010, 98, 109a.	0.2	0
122	Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: Implications for mitochondrial dysfunction in Parkinson disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 699-706.	1.8	67
123	Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochemical and Biophysical Research Communications, 2010, 394, 424-428.	1.0	83
124	Pathogenic Mutations Shift the Equilibria of αâ€ S ynuclein Single Molecules towards Structured Conformers. ChemBioChem, 2009, 10, 176-183.	1.3	71
125	Interaction Between α-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinson's Disease. NeuroMolecular Medicine, 2009, 11, 239-251.	1.8	64
126	A protein-based oxygen biosensor for high-throughput monitoring of cell growth and cell viability. Analytical Biochemistry, 2009, 385, 242-248.	1.1	23

#	Article	IF	CITATIONS
127	Structural insights on physiological functions and pathological effects of ±â€synuclein. FASEB Journal, 2009, 23, 329-340.	0.2	129
128	Molecular Insights into the Interaction between α-Synuclein and Docosahexaenoic Acid. Journal of Molecular Biology, 2009, 394, 94-107.	2.0	59
129	Trapping tyrosinase key active intermediate under turnover. Dalton Transactions, 2009, , 6468.	1.6	24
130	Type-3 copper proteins as biocompatible and reusable oxygen sensors. Inorganica Chimica Acta, 2008, 361, 1116-1121.	1.2	15
131	Conformational Equilibria in Monomeric α-Synuclein at the Single-Molecule Level. PLoS Biology, 2008, 6, e6.	2.6	181
132	Role of the tertiary structure in the diphenol oxidase activity of Octopus vulgaris hemocyanin. Archives of Biochemistry and Biophysics, 2008, 471, 159-167.	1.4	15
133	Broken Helix in Vesicle and Micelle-Bound α-Synuclein: Insights from Site-Directed Spin Labeling-EPR Experiments and MD Simulations. Journal of the American Chemical Society, 2008, 130, 6690-6691.	6.6	69
134	The Reaction of \hat{I}_{\pm} -Synuclein with Tyrosinase. Journal of Biological Chemistry, 2008, 283, 16808-16817.	1.6	116
135	Molecular Basis of the Bohr Effect in Arthropod Hemocyanin. Journal of Biological Chemistry, 2008, 283, 31941-31948.	1.6	13
136	Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine. Journal of Biological Chemistry, 2007, 282, 15597-15605.	1.6	254
137	X-ray absorption analysis of the active site of Streptomyces antibioticus Tyrosinase upon binding of transition state analogue inhibitors. Archives of Biochemistry and Biophysics, 2007, 465, 320-327.	1.4	18
138	Structural Features that Govern Enzymatic Activity in Carbonic Anhydrase from a Low-Temperature Adapted Fish, Chionodraco hamatus. Biophysical Journal, 2007, 93, 2781-2790.	0.2	15
139	Tryptophan-to-Dye Fluorescence Energy Transfer Applied to Oxygen Sensing by Using Type-3 Copper Proteins. Chemistry - A European Journal, 2007, 13, 7085-7090.	1.7	25
140	Structure and topology of the non-amyloid-β component fragment of human α-synuclein bound to micelles: Implications for the aggregation process. Protein Science, 2006, 15, 1408-1416.	3.1	48
141	Molecular Evolution and Phylogeny of Sipunculan Hemerythrins. Journal of Molecular Evolution, 2006, 62, 32-41.	0.8	14
142	Mechanistic Insight into the Activity of Tyrosinase from Variable-Temperature Studies in an Aqueous/Organic Solvent. Chemistry - A European Journal, 2006, 12, 2504-2514.	1.7	31
143	Paramagnetic Properties of the Halide-Bound Derivatives of Oxidised Tyrosinase Investigated by1H NMR Spectroscopy. Chemistry - A European Journal, 2006, 12, 7668-7675.	1.7	12
144	Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. Journal of Neurochemistry, 2005, 93, 246-256.	2.1	103

#	Article	IF	CITATIONS
145	Quaternary structure and functional properties of Penaeus monodon hemocyanin. FEBS Journal, 2005, 272, 2060-2075.	2.2	27
146	MXAN Analysis of the XANES Energy Region of a Mononuclear Copper Complex:Â Applications to Bioinorganic Systems. Inorganic Chemistry, 2005, 44, 9652-9659.	1.9	16
147	A Topological Model of the Interaction between α-Synuclein and Sodium Dodecyl Sulfate Micellesâ€. Biochemistry, 2005, 44, 329-339.	1.2	112
148	Cloning, expression, purification, and spectroscopic analysis of the fragment 57–102 of human α-synuclein. Protein Expression and Purification, 2005, 39, 90-96.	0.6	8
149	Interaction between the Type-3 Copper Protein Tyrosinase and the Substrate Analoguep-Nitrophenol Studied by NMR. Journal of the American Chemical Society, 2005, 127, 567-575.	6.6	39
150	Stopped-flow Fluorescence Studies of Inhibitor Binding to Tyrosinase from Streptomyces antibioticus. Journal of Biological Chemistry, 2004, 279, 13425-13434.	1.6	26
151	New aspects of the reactivity of tyrosinase. Micron, 2004, 35, 141-142.	1.1	11
152	Structural role of the copper ions in the dinuclear active site of Carcinus aestuarii hemocyanin. Micron, 2004, 35, 43-44.	1.1	1
153	What are the structural features of the active site that define binuclear copper proteins function?. Micron, 2004, 35, 143-145.	1.1	4
154	Structural properties, conformational stability and oxygen binding properties of Penaeus monodon hemocyanin. Micron, 2004, 35, 53-54.	1.1	0
155	Spectroscopic Characterization of the Electronic Changes in the Active Site of Streptomyces antibioticus Tyrosinase upon Binding of Transition State Analogue Inhibitors. Journal of Biological Chemistry, 2003, 278, 7381-7389.	1.6	34
156	Structural Basis and Mechanism of the Inhibition of the Type-3 Copper Protein Tyrosinase from Streptomyces antibioticusby Halide Ions. Journal of Biological Chemistry, 2002, 277, 30436-30444.	1.6	43
157	Tyrosinase-catalyzed Oxidation of Fluorophenols. Journal of Biological Chemistry, 2002, 277, 44606-44612.	1.6	71
158	Oxidized Derivatives of Octopus vulgaris and Carcinus aestuarii Hemocyanins at pH 7.5 and Related Models by X-ray Absorption Spectroscopy. Biophysical Journal, 2002, 82, 3254-3268.	0.2	16
159	Comparison of the X-ray absorption properties of the binuclear active site of molluscan and arthropodan hemocyanins. Journal of Biological Inorganic Chemistry, 2002, 7, 120-128.	1.1	12
160	Interaction and coordination geometries for Ag(I) in the two metal sites of hemocyanin. FEBS Journal, 2000, 267, 1754-1760.	0.2	4
161	Molecular heterogeneity of the hemocyanin isolated from the king crabParalithodes camtschaticae. FEBS Journal, 2000, 267, 7046-7057.	0.2	16
162	Kinetic and paramagnetic NMR investigations of the inhibition of Streptomyces antibioticus tyrosinase. Journal of Molecular Catalysis B: Enzymatic, 2000, 8, 27-35.	1.8	46

#	Article	IF	CITATIONS
163	EPR study of the dinuclear active copper site of tyrosinase from Streptomyces antibioticus. FEBS Letters, 2000, 474, 228-232.	1.3	40
164	1 H NMR spectroscopy of the binuclear Cu(II) active site of Streptomyces antibioticus tyrosinase. FEBS Letters, 1999, 442, 215-220.	1.3	64
165	Isolation of the met-derivative intermediate in the catalase-like activity of deoxygenated Octopus vulgaris hemocyanin. Journal of Inorganic Biochemistry, 1998, 72, 211-215.	1.5	9
166	Understanding the Electronic Properties of the CuASite from the Soluble Domain of CytochromecOxidase through Paramagnetic1H NMRâ€. Biochemistry, 1998, 37, 7378-7389.	1.2	63
167	The Binding of Azide to Copper-Containing and Cobalt-Containing Forms of Hemocyanin from the Mediterranean Crab Carcinus Aestuarii. FEBS Journal, 1997, 247, 688-694.	0.2	5
168	Nitrite Reductase Activity of DeoxyCarcinus maenasHemocyanin:Â Formation of the Half-Met Derivative. Inorganic Chemistry, 1996, 35, 1393-1394.	1.9	4
169	Cobalt(II) Substituted Derivatives ofCarcinus maenasHemocyanin:Â Magnetic Characterization, Magnetooptic, and Kinetic Studies Regarding the Geometry of the Active Site. Inorganic Chemistry, 1996, 35, 7482-7492.	1.9	11
170	The Oxidation of Hemocyanin. Kinetics, Reaction Mechanism and Characterization of Met-Hemocyanin Product. FEBS Journal, 1995, 232, 98-105.	0.2	9
171	Structural characterization of mononuclear Cu(II) and its nitrite complex in the active site of Carcinus maenas hemocyanin. Biochemistry, 1995, 34, 1524-1533.	1.2	17
172	Investigation of Solid and Solution Structures of N-Substituted Cu(II) Salicyldimines by X-Ray Absorption Spectroscopy. Inorganic Chemistry, 1995, 34, 2377-2381.	1.9	6
173	Cu(II) coordination in arthropod and mollusk green half-methemocyanins analyzed by electron spin-echo envelope modulation spectroscopy. Biochemistry, 1995, 34, 1513-1523.	1.2	18
174	Low temperature optical spectroscopy of cobalt-substituted hemocyanin from Carcinus maenas. European Biophysics Journal, 1993, 22, 157.	1.2	4
175	The Binding of Cd(II) to the Hemocyanin of the Mediterranean Crab Carcinus maenas. Archives of Biochemistry and Biophysics, 1993, 302, 78-84.	1.4	6
176	Crystal structure and electron spin echo envelope modulation study of [Cu(II)(TEPA)(NO2)]PF6 (TEPA =) Tj ETQq hemocyanin. Journal of the American Chemical Society, 1993, 115, 2093-2102.	0 0 0 rgB 6.6	T /Overlock 1 55
177	Preparation and spectroscopic characterization of a coupled binuclear center in cobalt(II)-substituted hemocyanin. Biochemistry, 1992, 31, 9294-9303.	1.2	49
178	Circular dichroism and fluorescence studies to probe the conformational properties of Rhus vernicifera laccase. Inorganica Chimica Acta, 1992, 193, 237-243.	1.2	3
179	The aromatic circular dichroism spectrum as a probe for conformational changes in the active site environment of hemocyanins. BBA - Proteins and Proteomics, 1992, 1120, 24-32.	2.1	17
180	Cobalt-substituted derivatives of Carcinus hemocyanin. Biology of Metals, 1990, 3, 90-92.	1.1	0

#	Article	IF	CITATIONS
181	Waterâ€Soluble Melanin–Protein–Fe/Cu Conjugates Derived from Norepinephrine as Reliable Models for Neuromelanin of Human Brain <i>Locus Coeruleus</i> . Angewandte Chemie, 0, , .	1.6	1